Skip to content
DataLookout
Menu

NCT07934303

Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants with Treatment-emergent Adverse Events
Timeframe: Day 1 through 48-Week Post-Treatment Follow-Up

Secondary (1)

Change from Baseline in Frataxin Protein Expression

Arms and interventions

Part A: NBIB-223Experimental

Dose escalation in adult participants.

Part B: NBIB-223Experimental

Dose expansion in pediatric participants.

Part C: NBIB-223Experimental

Dose expansion in adult and/or pediatric participants with FA-related cardiomyopathy.

Drugs: NBIB-0000223

Sites

5 sites in 1 country